MKI67 and breast cancer: In our results, the combination of high immunopositivity for both securin and Ki-67 indicated a 4.3-fold risk of breast cancer death as compared with the prognostic value of low securin and Ki-67, suggesting that securin in combination with Ki-67 enhances the prognostic information derived from cell proliferation.